Bioventure, a subsidiary of our Healthcare Division, GlobalOne Healthcare Holding (GHH), has signed an exclusive licensing agreement with Cooper Pharma S.A. (Cooper) for Adalimumab. This agreement provides Cooper with exclusive rights to register, hold the marketing authorisation, and commercialise Adalimumab in Morocco. Bioventure, which specialises in biosimilars and speciality generics, in/out-licensing, tech transfer, and